Table 1. Clinical characteristics of the in vitro fertilization cycles in women with diminished ovarian reserve.
| Non-pregnancy (n=52) | Clinical pregnancy (n=11) | ET cancelled (n=28) | OPU cancelled (n=5) | P-value | |
|---|---|---|---|---|---|
| Age (yr) | 40 (28–46) | 35 (31–42)a) | 35 (29–45)a) | 40 (29–42) | 0.038b) |
| <35 | 11 (21.57) | 5 (45.5) | 12 (44.44) | 2 (40.0) | 0.092 |
| 35–39 | 14 (26.9) | 4 (36.4) | 6 (22.22) | 0 | |
| 40≤ | 27 (51.9) | 2 (18.2) | 8 (29.63) | 3 (60.0) | |
| Serum AMH (ng/mL) | 0.75 (0–1.26) | 0.84 (0.15–1.26) | 0.35 (0–1.26) | 0.15 (0–0.89) | 0.113b) |
| Serum FSH (mIU/mL) | 11.6 (5.0–60.8) | 11.9 (5.0–39.4) | 19.8 (6.0–76.7)a),c) | 18.6 (6.5–76.7) | 0.018 |
| Serum E2 (pg/mL) | 65.27±85.13 | 42.45±23.51 | 59.52±71.27 | 30.0±22.77 | 0.832 |
| Total AFC (n) | 4.61±2.19c) | 7.09±2.63 | 3.93±2.91c) | 3.20±1.30c) | 0.005 |
| Total Gn dose (IU) | 2,421.63±1814.67 | 3,013.63±1,373.88 | 1,319.44±1,334.24a),c) | 180±268.33a),c) | 0.001 |
| Stimulation days | 10.69±3.83 | 10.81±1.66 | 11.30±5.80 | 13.6±4.39 | 0.563 |
| Peak E2 on day of hCG administration (pg/mL) | 1,406.9±1051.93 | 1,870.82±1,581.66 | 577.35±493.18 44 | 2.50±208.60a) | 0.031 |
| Total oocytes retrieved (n) | 3 (1–11) | 4 (2–6) | 1 (0–5)a),c) | <0.0001b) | |
| No. of MII (n) | 2 (0–8) | 2 (0–5) | 1 (0–2)a),c) | <0.0001b) | |
| No. of 2PN (n) | 2 (0–7) | 2 (0–5) | 0 (0–1)a),c) | <0.0001b) | |
| CES | 40.02±26.88 | 41.82±27.63 | 0a),c) | 0.016 | |
| TMSC (million) | 137.97±154.04 | 213.57±182.13 | 114.70±128.59 | 0.486 | |
| COH protocol | 0.002 | ||||
| Conventional stimulation | 34 (65.4) | 10 (46.4) | 13 (46.4) | 0 | |
| Soft/natural stimulation | 18 (34.6) | 1 (53.6) | 15 (53.6) | 5 (100) | |
| Cause of infertility | 0.305 | ||||
| Unexplained | 22 (42.3) | 5 (45.5) | 17 (63) | 1 (20) | |
| EMS | 21 (40.4) | 5 (45.5) | 8 (29.6) | 4 (80) | |
| Male factor | 9 (17.3) | 1 (9.1) | 2 (7.4) | 0 (0) | |
| Cause of diminished ovarian reserve | 0.01 | ||||
| Aging | 33 (65.4) | 3 (27.3) | 11 (39.3) | 3 (60) | |
| 36 (57.1) | 14 (42.4) | ||||
| Previous ovarian surgery | 9 (15.4) | 5 (45.5) | 4 (14.3) | 0 (0) | |
| 14 (22.2) | 4 (12.1) | ||||
| Idiopathic | 10 (19.2) | 3 (27.3) | 9 (33.3) | 1 (20) | |
| 13 (20.6) | 10 (30.3) | ||||
| Previous chemotherapy | 0 (0) | 0 (0) | 4 (14.3) | 1 (20) | |
| 0 (0) | 5 (15.2) | ||||
Data are presented as median (range), mean±standard deviation, or number (%).
ET, embryo transfer; OPU, oocyte pickup; AMH, anti-Müllerian hormone; FSH, follicle-stimulating hormone; E2, estradiol; AFC, antral follicle count; Gn, gonadotropin; hCG, human chorionic gonadotropin; MII, metaphase II; PN, pronuclei; CES, cumulative embryo score; TMSC, total motile sperm count; COH, controlled ovarian hyperstimulation; EMS, endometriosis.
a)Comparison with the non-pregnancy group by post hoc analysis; b)Kruskal-Wallis test was performed, and data are expressed as median (range); c)Comparison with the clinical pregnancy group by post hoc analysis.